Skip to main content
. 2019 Jan 18;14(1):e0210209. doi: 10.1371/journal.pone.0210209

Fig 8. Lapatinib does not suppress T lymphocyte activation or function.

Fig 8

A) IFN-γ ELISPOT assayof unfractionated human PBMCs from four unique donors stimulated with MHC class I recall peptides or tetanus toxoid protein in the presence of 2μM lapatinib. B) Composite data of the number of IFN-ɣ spot forming cells(normalized to control)from the same four donors. C) Flow cytometry analysis of allogenic DC:T cell co-cultures from three unique allogeneic stimulator:responder pairs with staining for CD4 (x axes) and CD69 (y axes). Percentage values indicate proportion of double-positive cells. D)ELISA analysis of IFN-ɣ production from four unique allogeneic stimulator:responder pairs in the presence or absence of lapatinib.